Virscio
Sven Korte, Dr. PhD., has extensive work experience in the field of toxicology and research. Sven currently holds the position of Senior Director of Research and Safety Assessment at Virscio, a translational research organization specializing in disease modeling and preclinical research for the pharmaceutical and life sciences industry. Prior to their current role, they spent 24 years at Labcorp Drug Development as a Senior Study Director for Primate Toxicology and SME Non-Systemic Delivery in NHP's. Sven also worked as a trainee study director and animal technician at Covance Laboratories, and as a field research assistant at the Institute of Marine Biology in Denmark and Italy. Additionally, they served as a research diver at the Barbados Bellairs Research Institute of McGill University and an animal technician in primate toxicology at Covance Laboratories in Washington D.C.
Sven Korte, Dr. PhD., completed their education in a chronological order as follows:
From 1980 to 1988, Sven Korte attended Kant Gymnasium, where they obtained their Abitur degree.
Starting from 1990 until 1996, Sven Korte pursued their studies at the University of Kassel, where they obtained their Dr. rer. nat. degree in the field of Zoology.
In 2006, Sven Korte enrolled in the British Toxicology Society to further enhance their expertise. Sven completed the program and became a European Registered Toxicologist.
No end year is provided for their education at the British Toxicology Society, indicating that Sven Korte may still be actively engaged in expanding their knowledge in this field.
This person is not in any teams
This person is not in any offices
Virscio
1 followers
Virscio is a specialty translational research organization developing and providing innovative in vivo disease modeling and related preclinical research and development services to meet the preclinical, translational, and regulatory research needs of the pharmaceutical and life sciences industry. We specialize in the fields of ophthalmology, central nervous system, cardiovascular and metabolic related disease and disorders, and have advanced discovery and development programs for a wide range of sponsors, collaborators, and partners around the world, ranging from large pharmaceutical companies and venture-backed biotechnology companies to academic teams seeking to apply the most cutting edge research and development strategies in the most efficient and robust manner.